Breaking News

Shots Fired at Canada War Memorial, Soldier Down
Tweet TWEET

Extension Study Data, Financial Results, Scheduled Conferences and Presentations - Research Report on Keryx, Raptor, Pacira,

      Extension Study Data, Financial Results, Scheduled Conferences and
Presentations - Research Report on Keryx, Raptor, Pacira, Horizon Pharma, and
                                    Impax

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, November 13, 2013

NEW YORK, November 13, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Keryx
Biopharmaceuticals Inc. (NASDAQ: KERX), Raptor Pharmaceuticals Corp. (NASDAQ:
RPTP), Pacira Pharmaceuticals Inc. (NASDAQ: PCRX), Horizon Pharma, Inc.
(NASDAQ: HZNP), and Impax Laboratories Inc. (NASDAQ: IPXL). Today's readers
may access these reports free of charge - including full price targets,
industry analysis and analyst ratings - via the links below.

Keryx Biopharmaceuticals Inc. Research Report

On November 8, 2013, Keryx Biopharmaceuticals Inc. (Keryx) announced
preliminary, unaudited data from its ongoing 48-week safety extension study of
Zerenex (ferric citrate coordination complex) - Keryx's drug candidate for
treatment of hyperphosphatemia in patients with chronic kidney disease on
dialysis. The Company stated that the data demonstrated Zerenex's ability to
significantly reduce the need for IV iron and ESAs, while maintaining
hemoglobin in dialysis patients. Ron Bentsur, the Company's CEO, commented,
"While preliminary, I believe that the data from this OLE study to date
reinforces the data observed in the long-term Phase 3 study. Importantly, it
is encouraging to see that Zerenex appears to be safe and well tolerated for
up to two years of cumulative exposure in clinical studies." The Company
informed that its New Drug Application for the use of Zerenex is currently
under FDA review with an assigned Prescription Drug User Fee Act goal date of
June 7, 2014. The Full Research Report on Keryx Biopharmaceuticals Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:

[http://www.analystscorner.com/r/full_research_report/27d2_KERX]

--

Raptor Pharmaceuticals Corp. Research Report

On November 7, 2013, Raptor Pharmaceuticals Corp. (Raptor Pharmaceuticals)
reported its Q3 2013 financial results and provided updates on PROCYSBI(R)
launch. PROCYSBI net product sales were reported at $6.6 million. Net loss for
the quarter totaled $17.3 million or $0.29 per share compared to net loss of
$10.2 million or $0.21 per share in Q3 2012. Christopher M. Starr, Ph.D.,
Raptor's CEO commented, "With the first full quarter of PROCYSBI sales now
complete, I am very pleased with the pace of the launch and our team's
performance. We continue to make significant strides in providing access to
PROCYSBI and communicating its benefits to both caregivers and patients, which
bodes well for our future success. Beyond cystinosis, our Phase 2/3 trial in
Huntington's disease is progressing well and we expect to have top-line data
in the first quarter of 2014, followed up by full enrollment of our pediatric
non-alcoholic fatty liver disease trial." The Company stated that data from
its Phase 2/3 study of PROCYSBI (RP103) in Huntington's disease following the
first 18 months of treatment are anticipated in Q1 2014. The Full Research
Report on Raptor Pharmaceuticals Corp. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at:

[http://www.analystscorner.com/r/full_research_report/a001_RPTP]

--

Pacira Pharmaceuticals Inc. Research Report

On November 8, 2013, Pacira Pharmaceuticals, Inc. (Pacira) announced its
President and CEO, David Stack is scheduled to present at the Jefferies 2012
Global Healthcare Conference in London on November 15, 2013 at 9:20 a.m. GMT
(4:20 a.m. ET). Pacira stated that Mr. Stack is expected to present an
overview of the Company. Pacira informed that a live audio webcast of the
presentation can be accessed at the Company's website, and its replay will be
archived for two weeks after the presentation date on the same location. The
Full Research Report on Pacira Pharmaceuticals Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at:

[http://www.analystscorner.com/r/full_research_report/c0aa_PCRX]

--

Horizon Pharma, Inc. Research Report

On November 8, 2013, Horizon Pharma, Inc. (Horizon Pharma) reported its Q3
2013 financial results with net sales of $26.2 million, up 302.1% YoY. Net
sales of Duexis and Rayos for the quarter totaled $23.5 million and $2 million
respectively, up 122% and 268% YoY. According to the Company, the increase in
DUEXIS sales during the Q3 2013 compared to Q3 2012 was primarily the result
of the Company's expanded sales force in addition to product price increases
implemented during the course of 2013. Net loss for the quarter was $5.5
million or $0.08 per share compared to $17 million or $0.47 per share in Q3
2012. Timothy P. Walbert, Chairman, President and CEO, Horizon Pharma stated,
"We achieved continued acceleration in prescriptions and revenue in the third
quarter, with both DUEXIS and RAYOS seeing significant growth in net revenue
on a sequential quarter over quarter basis. This sales growth, along with
improvement in the bottom line and cash burn, continues our momentum toward
becoming a profitable company." The Full Research Report on Horizon Pharma,
Inc. - including full detailed breakdown, analyst ratings and price targets -
is available to download free of charge at:

[http://www.analystscorner.com/r/full_research_report/05ea_HZNP]

--

Impax Laboratories Inc. Research Report

On November 7, 2013, Impax Laboratories, Inc. (Impax) announced its scheduled
presentation at the Credit Suisse Healthcare Conference which will be held in
Scottsdale, Arizona. The Company stated that it will present on Thursday,
November 14, 2013 at 9:30 a.m. MST at the conference and a live audio webcast
and archived presentation made at the conference will be available at the
Company's website under the investor relations section. The Full Research
Report on Impax Laboratories Inc. - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:

[http://www.analystscorner.com/r/full_research_report/4c54_IPXL]

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we
    are only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.

1.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
2.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
3.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Namrata Maheshwari,
CFA, has only reviewed the information provided by Equity News Network in this
article or report according to the Procedures outlined by Equity News Network.
Equity News Network is not entitled to veto or interfere in the application of
such procedures by the outsourced provider to the articles, documents or
reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

AnalystsCorner.com

SOURCE Analysts' Corner

Contact: Joe Thomas, CONTACT PHONE: +1-310-496-8071 (North America)
 
Press spacebar to pause and continue. Press esc to stop.